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Introduction: Mesenchymal stromal cells (MSC) are an integral cellular component of the tumor microenvironment.
Nevertheless, very little is known about MSC originating from human malignant tissue and modulation of these
cells by tumor-derived factors. The aim of this study was to isolate and characterize MSC from head and neck
squamous cell carcinoma (HNSCC) and to investigate their interaction with tumor cells.
Methods: MSC were isolated from tumor tissues of HNSCC patients during routine oncological surgery.
Immunophenotyping, immunofluorescence and in vitro differentiation were performed to determine whether the isolated
cells met the consensus criteria for MSC. The cytokine profile of tumor-derived MSC was determined by enzyme-linked
immunosorbent assay (ELISA). Activation of MSC by tumor-conditioned media was assessed by measuring cytokine release
and expression of CD54. The impact of MSC on tumor growth in vivo was analyzed in a HNSCC xenograft model.
Results: Cells isolated from HNSCC tissue met the consensus criteria for MSC. Tumor-derived MSC constitutively
produced high amounts of interleukin (IL)-6, IL-8 and stromal cell-derived factor (SDF)-1α. HNSCC-derived factors
activated MSC and enhanced secretion of IL-8 and expression of CD54. Furthermore, MSC provided stromal support
for human HNSCC cell lines in vivo and enhanced their growth in a murine xenograft model.
Conclusions: This is the first study to isolate and characterize MSC from malignant tissues of patients with HNSCC. We
observed cross-talk of stromal cells and tumor cells resulting in enhanced growth of HNSCC in vivo.Introduction
Mesenchymal stromal cells (MSC) are multipotent,
fibroblast-like progenitor cells that can differentiate into
multiple lineages, including osteogenic, adipogenic and
chondrogenic cell types. MSC express specific cell surface
markers such as CD29, CD73, CD90 and CD105 while
lacking hematopoietic markers such as CD14, CD34 and
CD45 [1]. Initially described as multipotent stromal cells
originating from the bone marrow, MSC were later iso-
lated from various fetal and adult tissues, including the
salivary gland, placenta, umbilical cord blood, muscle, adi-
pose tissue, connective tissue and peripheral blood [2-7].
Recently, MSC were also identified in pathological tissues* Correspondence: Sven.Brandau@uk-essen.de
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unless otherwise stated.and were found to be actively recruited towards tumors
and inflammatory microenvironments [8-11].
The functions of MSC within the tumor microenvi-
ronment are very complex and still require extensive
characterization [12]. For instance, MSC can differentiate
into endothelial or vascular smooth muscle cells and
might be critically involved in angiogenic processes [13].
Furthermore, MSC might have strong immunoregulatory
effects on both innate and adaptive immune cells as they
were shown to modulate the proliferation of T cells, B cells
or natural killer cells by releasing various cytokines and
metabolites of the arachidonic acid pathway [14-16]. The
strong modulatory potential of MSC is further highlighted
by their ability to release either proinflammatory or anti-
inflammatory factors in response to different types of
stimulation [17]. Altogether, these findings indicate that
MSC engage in a multidirectional communication withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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play an important role in the progression of solid tumors.
Indeed, a number of recent studies demonstrated that
MSC enhanced tumor growth and metastasis in several
types of cancer [9,18-23]. MSC exerted these tumor-
promoting effects by enhancing angiogenesis, inducing
immunosuppression or inhibiting the apoptosis of tumor
cells [22,24,25]. In sharp contrast, other studies found that
MSC had potent antitumor effects by inhibiting angio-
genesis, promoting antitumor immune responses and in-
ducing apoptosis of the cancer cells [26-33]. A possible
explanation for this discrepancy may be the variability of
MSC depending on the tissue and the microenvironment
from which they were isolated [34]. Additionally, some
variability might exist between human MSC and MSC de-
rived from murine tissues – which have been used in
many of the previous studies. Because of these caveats, the
exact effects of human tumor-resident MSC on the pro-
gression of human tumors remain unclear and need to be
further investigated.
In this study, we isolated for the first time MSC from
tumor tissues of patients with head and neck squamous
cell carcinoma (HNSCC). The isolated cells met the con-
sensus criteria for MSC [35] and were successfully main-
tained and propagated in vitro. These tumor-derived
mesenchymal stromal cells (TuMSC) exhibited a proin-
flammatory phenotype and responded to stimulation by
tumor cells with a strong interleukin (IL)-8 release and
with CD54 upregulation, respectively. Most importantly,
TuMSC significantly enhanced the growth of human
HNSCC lines when xenografted into recipient animals
in vivo. Our data thus suggest a bidirectional interaction
of MSC and tumor cells that, ultimately, results in the
progression of HNSCC.
Materials and methods
Ethic statement
Human HNSCC tissue was obtained from surgical speci-
mens after patients’ written informed consent using guide-
lines approved by the Ethics Committee of the University
Hospital of Essen.
Isolation of mesenchymal stromal cells
Head and neck cancer tissue samples were collected
aseptically in sodium chloride (0.9%; Fresenius Kabi, Bad
Homburg, Germany). Subsequently, tumor specimens
were washed several times with Ringer’s solution (Braun,
Melsungen, Germany) to remove the majority of erythro-
cytes. Tissues were cut into 1 to 2 mm pieces, washed exten-
sively and digested in Ringer’s solution containing 5 mg/ml
collagenase type II (CellSystems, Troisdorf, Germany) for
40 minutes at 37°C with gentle shaking. Tissues were centri-
fuged at 300 × g for 7 minutes, and the supernatant was
discarded. The partially digested tissues were further treatedwith Ringer’s solution and 33 mg/ml dispase (Roche Applied
Science, Mannheim, Germany) for 60 minutes at 37°C. The
cell suspension was then centrifuged, and the pellet was
resuspended in standard culture medium (high-glucose
Dulbecco’s modified Eagle’s medium; Invitrogen, Karlsruhe,
Germany) supplemented with 10% fetal bovine serum
(Biochrom, Berlin, Germany), 1% penicillin/streptomycin
(Invitrogen) and 1% sodium pyruvate (Invitrogen) and was
transferred to tissue culture flasks. Nonadherent cells were
removed by washing with phosphate-buffered saline 48 hours
later and fresh medium was added to the remaining cells.
During the culture period, cells were maintained at 37°C in a
humidified atmosphere of 5% carbon dioxide. Cells were
continuously passaged after reaching subconfluency by
StemPro® Accutase® Cell Dissociation Reagent (Invitrogen)
treatment for 5 minutes at 37°C. Bone-marrow-derived
mesenchymal stromal cells (BMMSC) were obtained by a
standard procedure as described previously [36].Flow cytometry
Direct immunofluorescence was performed for flow cy-
tometric cell-surface marker immunophenotyping using
the following specific monoclonal antibodies: CD14 PE
(clone M5E2), CD19 PE (clone HD37), CD73 PE (clone
AD2), CD90 (Thy-1) (clone 5E10) (all BD Bioscience,
Heidelberg, Germany), CD34 fluorescein isothiocyanate
(clone 581; Invitrogen/Molecular Probes), CD45 PE (clone
5B1; Miltenyi, Bergisch Gladbach, Germany) and CD105
fluorescein isothiocyanate (clone 166707; R&D Systems,
Wiesbaden, Germany). To determine nonspecific signals,
isotype controls were used at the same concentration as
that used for the specific antibody. Analysis was per-
formed using a FACS Canto II Flow Cytometer (BD Bio-
science) and the resulting data were processed using Diva
6 software (BD Bioscience).
Immunofluorescence microscopy
Cells were immunostained for Vimentin (1:200; mouse
monoclonal clone VIM13.2; Sigma-Aldrich, Taufkirchen,
Germany), S100A4 (1:100, rabbit polyclonal antibody;
Abcam, Cambridge, UK), secondary antibody goat anti-
mouse IgG fluorescein isothiocyanate (1:100; Dianova,
Hamburg, Germany) and goat anti-rabbit IgG Cy3 bis-
NHS ester (Cy3) (1:1,000; Dianova). Cells were examined
with an Axioskop 2 microscope with a Ph2 Plan-Neofluar
20×/0.5 objective lens (Carl Zeiss MicroImaging, Göttingen,
Germany). Images were generated using an Axiocam MRc
microscope camera and Axiovision AxioVS40 Software
(Carl Zeiss MicroImaging).
Trilineage in vitro differentiation
Differentiation towards osteogenic, adipogenic and chon-
drogenic lineage was induced as described previously [37].
Table 1 Clinical information for tumor-derived mesenchymal
stromal cell donors
Patient number Localization T N M Entity Grading
1 Oral cavity 4 1 0 SCC G3
2 Hypopharynx 4 0 0 SCC G2
3 Oropharynx 2 1 0 SCC G3
4 Oropharynx 4 3 0 SCC G2
5 Hypopharynx 3 2 0 SCC G2
6 Oropharynx 2 1 0 SCC G2
7 Oropharynx 3 3 0 SCC G3
G2, moderately differentiated cells; G3, poorly differentiated cells; SCC,
squamous cell carcinoma.
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on round glass slides in 12-well culture dishes (Greiner
Bio-One, Frickenhausen, Germany). For osteogenic differ-
entiation, cells were cultured for 21 days in Mesenchymal
Stem Cell Osteogenic Differentiation Medium (PromoCell,
Heidelberg, Germany). Medium change was performed
every 3 to 4 days. Cells were finally stained with alizarin
red S solution for 2 minutes to confirm the formation of
calcium phosphate salts.
For adipogenic differentiation, we used Mesenchymal
Stem Cell Adipogenic Differentiation Medium (PromoCell)
for 14 days. To examine the generation of oil droplets in
the cytoplasm after differentiation, cells were fixed with
10% formalin (Sigma-Aldrich) and stained with Sudan-III
(Sigma-Aldrich) for 20 minutes at room temperature.
Hematoxylin (Thermo Scientific, Bonn, Germany) was used
to visualize nuclei.
Chondrogenic differentiation was induced after 48 hours
of culture in standard medium supplemented with dexa-
methasone, 1 × 10−3 ML-proline (Sigma-Aldrich), 10 ng/ml
transforming growth factor-β3 (Sigma-Aldrich) and 1% BD
ITS Culture supplement (BD Bioscience). Medium change
was performed every 3 to 4 days. To demonstrate the pres-
ence of glycosaminoglycans, Alcian blue staining was used.
Dried 5 μm cryosections of the micromass pellets were fixed
with formalin and washed with phosphate-buffered saline.
Staining with Alcian blue 8GX (Roth, Karlsruhe, Germany)
was performed at room temperature for 60 minutes.
Cytokine profiling of mesenchymal stromal cells
After isolation and cultivation as described above, medium
was exchanged and supernatant was collected from three
different patient samples of MSC over a period of 24 hours.
Cytokine secretion was analyzed with a bead-based multi-
plex assay (Bio-Plex; Bio Rad, Hercules, CA, USA) accord-
ing to the manufacturer’s instructions.
Stimulation of MSC with tumor-conditioned medium
TuMSC from different patient samples (see Table 1) were
incubated in the presence of supernatants obtained from
the HNSCC cell lines FaDu (ATCC HTB-43) and UM-SSC-
22B (kindly provided by TK Hoffmann, University of Ulm,
Germany). After 36 to 48 hours, tumor-conditioned
medium was discarded and replaced by standard culture
medium (high-glucose Dulbecco’s modified Eagle’s medium;
Invitrogen) supplemented with 10% fetal bovine serum
(Biochrom), 1% penicillin/streptomycin (Invitrogen) and 1%
sodium pyruvate (Invitrogen). The control group was incu-
bated for the same time period in standard culture medium.
After 24 hours, medium was collected or cells were har-
vested. IL-8 secreted by activated MSC was measured by
enzyme-linked immunosorbent assay (R&D Systems). Ex-
pression of CD54 (clone HA58; eBioscience, Frankfurt,
Germany) on MSC was analyzed by flow cytometry.Murine xenograft model
Equal numbers of MSC isolated from three different pa-
tient samples were pooled and resuspended in fresh
medium. TuMSC/BMMSC and HNSCC FaDu cells were
mixed in a 1:1 ratio, resuspended in phosphate-buffered
saline at a concentration of 106 cells/100 μl and injected
subcutaneously into the right flank of immunodeficient
nude mice (TuMSC/BMMSC, n = 8/n = 4). A control
group (n = 8) was injected with 0.5 × 106 FaDu cells only.
The tumor volume was calculated each day using the
following formula:
v ¼ π
6
n o
 w2  l
where V is volume, w is width, and l is length. After
35 days (45 days for control group), mice were sacrificed
and the tumors were analyzed. Early termination at day
35 for the MSC/HNSCC group was required by local
animal ethics regulations. Animal experiments were ap-
proved by the responsible animal ethics committee of
the state of North Rhine-Westphalia and carried out ac-
cording to German guidelines for experimental animal
welfare.
Histology
Murine xenograft tumors were stained for Ki-67 and ter-
minal deoxynucleotidyl transferase-dUTP nick end-labeling
(TUNEL) as markers for proliferation rates and cell death.
Anti-Ki-67 antibody MIB-1 mouse anti-human (1:100;
Dako, Hamburg, Germany) was used as primary antibody,
followed by peroxidase-conjugated rabbit anti-mouse (1:50;
Dianova) and goat anti-rabbit (1:50; Dianova) secondary
antibodies. Hematoxylin and eosin counterstaining was
performed for nucleus identification. Frequency of Ki-
67-positive cells as percent of total cells was calculated
using three representative images per sample.
Staining for TUNEL was performed with the Apo-Direct
Kit© (BD Bioscience) according to the manufacturer’s in-
structions. The TUNEL-positive area was calculated with
Image J (Fiji, open source, http://imagej.net/Fiji) software.
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Isolation and characterization of MSC from HNSCC tissues
We first explored whether MSC can be obtained from ma-
lignant tissue of HNSCC patients employing standard iso-
lation protocols for MSC. The isolated cells showed plastic
adherence under standard culture conditions with a typical
fibroblast-like morphology. To test whether the isolated
cells expressed surface markers characteristic for MSC,Figure 1 Immunophenotyping of head and neck squamous cell carcino
(MSC) were isolated from malignant tissue of patients with head and neck sq
was performed by flow cytometry. Data depicted as histograms. (b) Tumor-de
for vimentin and S100A4 was performed. Data and images from one representhese cells were subjected to flow cytometric analysis.
We found that the isolated cells expressed MSC surface
markers such as CD73, CD90 and CD105 and lacked the
expression of hematopoietic markers such as CD14, CD19,
CD34, CD45 and HLA class II (Figure 1a). Immunofluor-
escence analysis revealed the expression of further mesen-
chymal markers characteristic for MSC, such as vimentin
and S100A4 (Figure 1b). An important criterion for MSCma-derived mesenchymal stromal cells. Mesenchymal stromal cells
uamous cell carcinoma and were expanded. (a) Immunophenotyping
rived MSC were seeded on cover slips and immunofluorescence staining
tative experiment are shown.
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ation capacity. Under differentiation-inducing conditions,
the isolated cells were tested for their chondrogenic, osteo-
genic and adipogenic multipotency. As shown in Figure 2,
these cells could be induced to differentiate into all three
lineages. Taken together, these studies established for the
first time the expansion of MSC isolated from malignant
tissue of patients with HNSCC.
Cytokine profiling of TuMSC and modulation by
tumor-derived factors
MSC exert their immunoregulatory activity partly via
release of cytokines. Cytokine profiling of TuMSC re-
vealed high constitutive expression of inflammatory
cytokines (IL-6, IL-8, tumor necrosis factor alpha),
homeostatic chemokines (stromal cell-derived factor-
1α) and T-helper type 1 cytokines (interferon gamma)
(Figure 3b). A number of other T-cell-modulating cy-
tokines either were not expressed (IL-5, IL-7, IL-10,Figure 2 Trilineage differentiation of head and neck squamous cell ca
mesenchymal stromal cells were harvested and subjected to trilineage diffe
Top row: adipogenic differentiation after 14 days, staining performed with
staining with Alcian blue. Bottom row: osteogenic differentiation after 21 d
are shown.IL-12, IL-13, IL-17; data not shown) or were expressed
at low levels (IL-1β, IL-2, IL-4, granulocyte–macrophage
colony-stimulating factor, macrophage inflammatory
protein-1β; Figure 3a).
In the tumor microenvironment, TuMSC are likely to
be engaged in cross-talk with tumor cells. To investigate a
possible modulation of MSC by tumor cells, we exposed
TuMSC to conditioned media obtained from the HNSCC
cell lines FaDu and UM-SSC-22B and determined the sub-
sequent release of cytokines. Specifically, we assessed the
levels of IL-8 because this proinflammatory cytokine is
known to be released by MSC from various sources and is
involved in the modulation of the tumor microenviron-
ment [38]. As illustrated in Figure 4a, HNSCC cell line
supernatant strongly enhanced the release of IL-8 by
MSC. The cell–cell adhesion molecule CD54 (ICAM-1) is
a robust marker of activation in a large number of cell
types. We therefore examined regulation of CD54 expres-
sion in TuMSC exposed to tumor-conditioned medium.rcinoma-derived mesenchymal stromal cells. Tumor-derived
rentiation using standard differentiation-inducing culture conditions.
Sudan III. Middle row: chondrogenic differentiation after 14 days,
ays, staining with Alizarin red. Images from one representative donor
Figure 3 Cytokine profile of tumor-derived mesenchymal stromal
cells. Tumor-derived mesenchymal stromal cells obtained from three
individual patients were cultured for 24 hours and the culture
supernatant was harvested. Concentration of cytokines was analyzed
with a bead-based multiplex assay. Secretion was classified as no
secretion (IL-5, IL-7, IL-10, IL-12, IL-13, IL-17; data not shown), (a) low
secretion (<100 pg/ml) and (b) high secretion (>100 pg/ml). Data
depicted as mean ± standard deviation. G-CSF, granulocyte
colony-stimulating factor; GM-CSF, granulocyte–macrophage colony-
stimulating factor; IFN, interferon; IL, interleukin; MIP-1 β, macrophage
inflammatory protein-1β; SDF-1α, stromal cell-derived factor-1α; TNFα,
tumor necrosis factor alpha; VCAM1, vascular cell adhesion molecule 1.
Figure 4 Activation of tumor-derived mesenchymal stromal cells
by head and neck squamous cell carcinoma-conditioned medium.
Individual tumor-derived mesenchymal stromal cell (TuMSC) lines were
incubated in the presence of culture supernatants obtained from head
and neck squamous cell carcinoma cell lines. After 36 to 48 hours, the
FaDu/UM22B conditioned supernatant was aspirated and replaced by
fresh standard culture medium. After another 24 hours, the TuMSC
culture supernatant (a) or TuMSC (b) was collected. Concentration of
interleukin (IL)-8 was measured by enzyme-linked immunosorbent
assay (a) and expression of CD54 on activated TuMSC was analyzed by
flow cytometry (b, c). The experiment was performed with TuMSC from
seven independent donors designated #1 to #7. APC, Allophycocyanin;
MFI, median fluorescence intensity; SN, supernatant.
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regulated surface expression of CD54 in all tested donors
(Figure 4b) both for FaDu and UM-SSC-22B supernatant.
As shown in Table 1, this activation occurred in MSC ob-
tained from tumor samples of various histopathological
background. In sum, these studies indicate that TuMSC
from HNSCC patients release large amounts of immuno-
modulatory cytokines and are strongly activated if exposed
to tumor-derived factors from HNSCC cell lines.
Tumor-derived MSC promote HNSCC growth in a murine
xenograft model
In the final part of the study we analyzed the impact of
TuMSC on the progression of HNSCC in vivo. In this
experiment we included BMMSC, for which tumor-
Figure 5 Effect of mesenchymal stromal cells on head and neck
squamous cell carcinoma progression in a xenograft murine
model. Equal numbers of mesenchymal stromal cells isolated from
three different patient samples were pooled and admixed to HNSCC
FaDu cells in a 1:1 ratio. Mixtures of tumor-derived mesenchymal
stromal cells (TuMSC)–FaDu cells (n = 8) and bone marrow-derived
mesenchymal stromal cells (BMMSC)–FaDu cells (n = 4) were injected
into the right flank of immunodeficient nude mice. The control
group was injected with only FaDu cells (n = 8). (a) The tumor
volume was monitored by caliper measurements. Gray vertical line,
sacrifice of mice according to ethic requirements. Cryosection slides
of excised tumors (n = 3 for each group) were analyzed for Ki-67
staining (b) and apoptosis TUNEL staining (c). Representative
pictures were chosen and analyzed under a 400-fold magnification.
p.i., post injection (of tumor); TUNEL, terminal deoxynucleotidyl
transferase-dUTP nick end-labeling.
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models [39,40], as a reference group. TuMSC/BMMSC
were coinjected with HNSCC cells (FaDu) into immuno-
deficient nude mice. As a control, a group of animals
was injected with HNSCC cells only. Tumor growth was
assessed in a time course. The results show a significant
difference in tumor growth between the three groups
of mice (Figure 5). Specifically, the majority of mice
injected with HNSCC cells and MSC developed palpable
tumors already between days 7 and 20, and reached a
high tumor volume around day 30. Owing to local ani-
mal ethics regulations, animals with FaDu/MSC tumors
had to be sacrificed at day 35 because of tumor size and
progression. In contrast, HNSCC cells lacking support
by MSC displayed significantly delayed growth, with
tumor growth starting around day 35 post injection.
Histologic sections showed differences in proliferation
rates and apoptosis between tumors coinjected with MSC
and FaDu-only tumors. As shown in Figure 5b, coinjected
tumors had a larger proliferative activity in comparison
with FaDu-only tumors. This difference was also observed
for TUNEL staining. These data demonstrate that primary
MSC isolated from human HNSCC tissues and bone
marrow provide substantial stromal support to promote
HNSCC growth in vivo.
Discussion
The histopathology of HNSCC is characterized by large
stromal compartments, which surround the tumor islands.
Only recently has it been fully recognized that the growth
and progression of carcinomas are not only determined by
the intrinsic properties of the tumor cells but critically de-
pend on their interaction with the stromal cells. More re-
cently, MSC have been recognized as important cellular
components of the tumor stroma [18,19]. As such, MSC
can promote tumor development and progression by vari-
ous means [12]. For instance, MSC directly modulate
tumor cell biology and enhance proliferation, invasion and
metastasis. MSC can also enhance angiogenesis by
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nally, MSC have very potent immunoregulatory properties
[41] and may downregulate antitumor immunity by a large
variety of immunosuppressive mechanisms [14-16].
One way in which MSC interact with the surrounding
cells in the tumor microenvironment is via release of cyto-
kines and chemokines. Consistent with this idea, MCS iso-
lated from our HNSCC patients released large amounts of
cytokines. It is also noteworthy that, on a per-cell basis,
this release may well exceed production of such cytokines
by tumor-infiltrating leukocytes. Cytokine profiling re-
vealed that IL-6, IL-8 and stromal cell-derived factor-1
were the most abundant cytokines secreted by the TuMSC
in our study. Interestingly, this group of cytokines has pre-
viously been reported to be involved in the recruitment of
MSC to the tumor site [8,11,42]. Still a matter of debate,
however, is whether MSC are actively recruited to the
tumor site or derive from tissue-resident precursors. While
it appears to be unlikely that the entire stroma of carcin-
omas is actively recruited from a distant site, elegant stud-
ies by several groups indicate at least a partial contribution
of bone-marrow derived cells to certain components of
the tumor stroma [9,20].
Irrespective of their origin, once present in the malignant
tissue MSC are exposed to tumor cells and are likely to be
engaged in a bidirectional interaction with those malignant
cells. In support of this hypothesis, we found a dramatic
upregulation of IL-8 release and of CD54 expression when
TuMSC were exposed to tumor-conditioned medium.
These findings are in agreement with a number of other
studies demonstrating that MSC can be functionally
modulated by tumor-derived factors [43-45].
During recent years, MSC have been isolated from a var-
iety of tissues. Many studies analyzing the interactions of
MSC with tumor cells used MSC derived from adipose
tissue (a readily available tissue from which MSC can be
easily isolated) or from bone marrow (where MSC were
originally identified and characterized). While MSC de-
rived from different sources share many common features
and properties, some functional heterogeneity does exist
depending on the tissue of origin [2,3,34]. This heterogen-
eity might also explain the contradictory findings regard-
ing the effect of MSC on cancer progression [34]. Here,
we investigated the effect of MSC derived from bone mar-
row and from malignant tissues of HNSCC patients on
the biology of the tumor cells. We clearly showed that
both types of MSC strongly promoted tumor growth
when coinjected with HNSCC cells into recipient mice.
Histologic observations showed histomorphological dif-
ferences between the tumors coinjected with MSC and
the FaDu-only tumors. Notably, coinjection of MSC re-
sults in a higher proliferation and apoptosis throughout
the sections, indicating a stimulating and metabolism pro-
moting role of MSC in the tumor microenvironment.Because very few studies have thus far analyzed human
tumor-resident MSC, our findings might shed new light
on how MSC modulate tumor progression in cancer
patients.
Conclusion
In this study, we isolated, expanded and characterized
for the first time MSC from human malignant HNSCC
tissues. This enabled us to assess basic biological func-
tions of these cells, to investigate their modulation by
tumor cells and to explore their effects on the growth of
human cancer xenografts in mice. Our findings thus
contribute to a better understanding of the tumor–
stroma interactions and, ultimately, may stimulate the
search for novel therapeutic strategies for HNSCC and
other types of cancer.
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